Quick Takeaways: Why It Matters? Lenivia strengthens Zoetis’ lead in monoclonal antibody–based pain management for dogs by adding a longer-acting OA option to its portfolio. Market-wise, a single injection providing up to three months of osteoarthritis pain...
The European Medicines Agency (EMA) is continuing to accelerate innovation in animal healthcare, with its 2025 veterinary approvals reflecting strong momentum across poultry vaccines, companion animal therapeutics, livestock disease prevention, and aquaculture solutions. The latest wave of...
Quick Takeaways Why It Matters? Medline’s move is a smart adjacency play: it brings a proven sterile-kitting model from human healthcare into animal health, where shelters and high-volume clinics care a lot about speed, consistency, and labor savings. The big ma...
Quick Takeaways Why It Matters? Gelteq’s animal health trial gives it a foothold in the large antiparasitic market and turns its gel-based platform into a potential formulation partner for veterinary pharma, not just nutraceuticals. If the data support a later FDA filing,...
Quick Takeaways Why It Matters? This deal gives Viromed a faster route to commercialize PulmoPlas in veterinary respiratory care, starting with horses, while NEBU-TEC gets exclusive global distribution rights in that segment. The biggest market upside is in ...
Quick Takeaways Why It Matters? A new proprietary CNS asset from Orion, exclusively commercialized by Zoetis in the US, that taps into fast‑growing demand for medical management of canine anxiety and should expand the addressable market beyond situational noise phobia toward mo...
Quick Takeaways Why It Matters? Ceva is using this JV to turn Japan from a peripheral presence into a true platform market, bolting its global livestock and pet portfolio onto Bussan Animal Health’s 75‑year brand, field force, and ~€40M business to create a full‑line ...
Quick Takeaways: Why It Matters? Volition is positioning Nu.Q Vet Feline as a potential first scalable, affordable blood test for feline lymphoma, with performance (86% sensitivity at 97% specificity) strong enough to support real-world screening, not just “rule...
Quick Takeaways Why It Matters? Gallant is on track to create one of the first mass‑market, disease‑modifying OA biologics in companion animals, shifting regenerative medicine from niche referral centers into everyday general practice via a simple, ready‑to‑use IV product. ...
Quick Takeaways: Why It Matters? Kennel Connection is turning routine pet care venues into access points for clinical‑grade diagnostics by embedding Petwealth’s at‑home PCR testing and AI insights directly into its management software used by thousands ...
